Kurzfassung

A Phase 3 Randomized, Double-Blind, Multicenter, Global Study of
Monalizumab or Placebo in Combination With Cetuximab in Patients WithRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckPreviously Treated With an Immune Checkpoint Inhibitor